Targeted polytherapy in small cell sarcoma and its association with doxorubicin
Open Access
- 10 June 2014
- journal article
- research article
- Published by Wiley in Molecular Oncology
- Vol. 8 (8) , 1458-1468
Abstract
A paradigm shift has occurred in the last decade from chemotherapy to targeted therapy for the management of many patients with advanced sarcoma. This work identifies a combination of targeted agents and doxorubicin that are effective against small cell sarcoma cell lines.Three small cell sarcoma cell lines were studied: RD18 (rhabdomyosarcoma), A204 (undifferentiated sarcoma) and TC 71 (Ewing's sarcoma). Each cell line was exposed to increasing concentrations of vorinostat (HDAC inhibitor), 17‐DMAG (HSP90 inhibitor), abacavir (anti‐telomerase) or sorafenib (tyrosine kinase inhibitor) alone, combined with one another, or combined with doxorubicin. Cell viability, cell cycle analysis and apoptosis were assessed by MTS assay, propidium iodide‐Annexin V staining, and caspase 3/7 activity, respectively. The Chou and Talalay combination index (CI) was used to determine whether the effects were additive (CI = 1), synergistic (CI < 1) or antagonistic (CI > 1).In monotherapy, targeted agents achieved 30–90% reductions in viability, with the exception of abacavir. Dual‐targeted combination therapies with vorinostat, sorafenib and 17‐DMAG demonstrated synergy. Abacavir was antagonistic with every other drug and was not further studied. Both vorinostat and 17‐DMAG synergized with doxorubicin, achieving 60% cell killing compared to 12% with doxorubicin alone. No synergy was observed for sorafenib with doxorubicin. The triple therapy vorinostat, 17‐DMAG and doxorubicin did not show synergy, but increased the subG1 population at 24H, from 30% to 70% compared to monotherapies with an increase in apoptosis.This work provides evidence of synergy of combinations of vorinostat, 17‐DMAG and sorafenib in small cell sarcoma. In addition to doxorubicin, these combinations enhance doxorubicin cytotoxicity at therapeutically relevant concentrations.Keywords
Funding Information
- Amschwand Sarcoma Cancer Foundation
- ARC Foundation for Cancer Research
This publication has 62 references indexed in Scilit:
- Management and outcome of 239 adolescent and adult rhabdomyosarcoma patientsCancer Medicine, 2013
- Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma CellsSarcoma, 2013
- A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomasEuropean Journal of Cancer, 2012
- A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancerInvestigational New Drugs, 2012
- Rare cancers are not so rare: The rare cancer burden in EuropeEuropean Journal of Cancer, 2011
- The Reverse Transcription Inhibitor Abacavir Shows Anticancer Activity in Prostate Cancer Cell LinesPLOS ONE, 2010
- Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapyClinical Epigenetics, 2010
- Histone Deacetylase InhibitorsDrugs, 2009
- Inhibitors of Deacetylases Suppress Oncogenic KIT Signaling, Acetylate HSP90, and Induce Apoptosis in Gastrointestinal Stromal TumorsCancer Research, 2009
- Telomerase in Cancer Diagnosis and TherapyBioDrugs, 1999